Journal of Clinical Virology
Volume 61, Issue 1 , Pages 55-60, September 2014
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus
Min-Min Yu
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Southeast University, Nanjing 210003, China
Corresponding Author author. Tel.: +86 13952040383; fax: +86 25 83468055.
Qian Jiang ,
Ying Ji ,
Kai-Hua Wu ,
Li-Li Ju ,
Xun Tang ,
Yong-Feng Yang
Received 28 March 2014; received in revised form 28 May 2014; accepted 3 June 2014. published online 16 June 2014.
Highlights
•The use of antiviral drugs in pregnancy.
•Telbivudine and lamivudine can reduce HBV DNA levels in pregnant women.
•Telbivudine and lamivudine can interrupt the vertical transmission of HBV.
Abstract
Background
Infection with hepatitis B virus (HBV) during pregnancy may lead to perinatal transmission.
Objectives
To compare the efficacy and safety of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
Study design
All pregnant women enrolled in this study were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). Test patients underwent antiviral therapy with telbivudine or lamivudine while control patients received hepatitis B immune globulin (HBIG) injection.
Results
Patients in the telbivudine group had significantly lower HBV DNA and HBeAg levels and higher HBV DNA negative conversion rates compared to those in the lamivudine group before delivery. HBV DNA negative conversion rates in patients with abnormal alanine aminotransferase (ALT) levels were significantly higher than those in patients with normal ALT levels in the telbivudine and lamivudine groups before delivery. The intrauterine HBV infection rate and the percentage of immunization failure were both 0% in the telbivudine and lamivudine groups (χ2=0, 0; P=1, 1 respectively), compared to both 5% in the HBIG group (χ2=11.83, 7.86; P=0.002, 0.009 respectively). The side effects of three groups in mother and child were all unobvious.
Conclusions
Telbivudine and lamivudine can reduce HBV DNA levels in pregnant women, interrupt the vertical transmission of HBV and be used safely in mothers and children. 作者: StephenW 时间: 2014-9-17 21:36
肝病学杂志《Hepatology》2007年第4期上刊登的美国乙型肝炎临床研讨会纪要(Management of hepatitis B: Summary of a clinical research workshop),在妊娠妇女用药的段落中(第1068页)专门写道:“拉米夫定、替比福定、恩曲他滨和替诺福韦被归入B类,提示在动物实验中未证实致畸作用,但在人类还缺乏足够的评估或正在进行的一些研究包含的妊娠病例太少不能提供可靠的临床证据。如果应用这些药物对于母亲和胎儿所带来的收益超过风险,则可以应用这些药物。替诺福韦对骨密度可能有影响,因此不建议妊娠和哺乳期使用。恩替卡韦和阿德福韦在动物实验中证实有胚胎和胎儿毒性,因此被归入C类,但是没有在人类前瞻性生殖毒的研究。”作者: atu1008 时间: 2014-9-21 23:18
替B可以怀孕服用,却不可以母乳期服用,是因为它有肌酸激酶升高风险,也影响孩子,难道就不会发生在怀孕期的吗?自相矛盾!替b的副作用毋庸置疑,耐药率和抗毒性比拉米好,是仅有的亮点。NT至少没有被证明对怀孕期间服用有影响,也许以后会被Food and drug administration us 批准!作者: atu1008 时间: 2014-9-22 07:41
【Author】 ZHANG Yan-li,YI Nuo,CAO Yan-jun,FANG Fang,CAI Hao-dong.Center of Liver Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China.Department of Obsterics and Gynecology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China